trending Market Intelligence /marketintelligence/en/news-insights/trending/t-ptqn9qulo1nheo756zng2 content esgSubNav
In This List

Therapix Biosciences director resigns

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery

Blog

EV impact; vaccines to boost job market; coal supply constraints

Blog

Shore Capital is Now Available in S&P Global’s Aftermarket Research Collection


Therapix Biosciences director resigns

Mark Groussman has resigned as a director of Therapix Biosciences Ltd.

Groussman's resignation was not related to any disagreement with the board on any matter relating to the operations, policies or practices, according to Therapix.

Tel Aviv, Israel-based Therapix Biosciences is a specialty clinical-stage pharmaceutical company that develops drugs based on cannabinoid molecules.